DDIT4 and glioblastoma: SLC2A3 has a poor prognosis in GBM, is significantly increased in cell lines treated with TMZ and DIDIT4 overexpression, and DDIT4 mediates the expression of SLC2A3 and reduces the toxicity of TMZ.